LikeMinds is a radiopharmaceutical product and technology development company that aims to provide a precise, early, accurate and ultimately actionable diagnosis of Parkinson’s Syndrome, dementia and other dopamine-related brain diseases. Our experimental DaT2020TM imaging agent product candidate is being investigated in a Phase 2b/3 clinical study intended to measure efficacy and success rates in diagnosing and characterizing dopamine receptor activity in the brain.
At LikeMinds, we view a patient’s tremor as the external symptom of a disease sparked long before its first clinical symptoms with a nearly undetectable, yet measurable dip in a brain’s ability to generate and receive normal brain cell signals. Along the way that story of an emerging brain disease may offer a series of moments, all chartable and trackable and many representing opportunities for care and intervention.
We’re passionately focused on helping clinicians see and mark that moment, offering clarity and precision, hopefully and possibly a long time before symptoms appear.